Newron :: Press Releases

Newron to initiate Phase IIb/III study of Ralfinamide in patients with Neuropathic Low Back Pain (NLBP) 22/12/2008	ENG	GER
Newron and partners awarded EUR 1 million by Regione Lombardia for R&D on innovative Nav 1.7 blockers for the treatment of pain 22/12/2008	ENG	GER
Change in Newron Group Management 19/12/2008	ENG	GER
Newron secures CHF30m long term standby equity line 03/12/2008	ENG	GER
Newron reports positive Phase II safety and tolerability results for HF0220 in Alzheimer’s disease 23/10/2008	ENG	GER
New Safinamide patent granted by European Patent Office (EPO) 15/10/2008	ENG	GER
Newron awarded EUR 5 million by the Italian government 08/10/2008	ENG	GER
Newron reports half-year results 2008 19/09/2008	ENG	GER
Newron to be included in SXI Life Sciences and SXI Bio+Medtech Indices of SWX 25/08/2008	ENG	GER
Newron announces completion of patient enrollment in phase III clinical trial of safinamide in mid- to late-stage Parkinson’s Disease 22/05/2008	ENG	GER
Newron closes acquisition of Hunter-Fleming 14/05/2008	ENG	GER
Newron acquisition of Hunter-Fleming. Upfront payment agreed. 29/04/2008	ENG	GER
Newron shareholders’ meeting 25/04/2008	ENG	GER
NEWRON TO BE INCLUDED IN SWISS PERFORMANCE INDEX OF THE SWISS STOCK EXCHANGE (“SWX”) EFFECTIVE 6 MAY 2008 23/04/2008	ENG	GER
Newron reports positive Phase II results for ralfinamide in peripheral neuropathic pain patients 16/04/2008	ENG	GER
Newron to present Phase II clinical data on ralfinamide in neuropathic pain at the AAN 09/04/2008	ENG	GER
NEWRON PHARMACEUTICALS REPORTS 2007 RESULTS 27/03/2008	ENG	GER
Data safety monitoring board recommends continuation of phase II study for HF0220 in patients with Alzheimer’s disease 03/03/2008	ENG	GER
Safinamide patent protection strengthened by EPO Intention-to-Grant-letter 26/02/2008	ENG	GER
Newron completes enrolment of clinical phase II study with ralfinamide in post-surgical (dental) pain 19/02/2008	ENG	GER
Newron acquires Hunter-Fleming Ltd 11/02/2008	ENG	GER
Dr. Hans-Joachim Lohrisch joins Newron’s Board of Directors 14/01/2008	ENG	GER

Discovering and developing innovative therapeutics for CNS disorders

Media

Press Releases - 2008

Newron to initiate Phase IIb/III study of Ralfinamide in patients with Neuropathic Low Back Pain (NLBP)

Newron and partners awarded EUR 1 million by Regione Lombardia for R&D on innovative Nav 1.7 blockers for the treatment of pain

Change in Newron Group Management

Newron secures CHF30m long term standby equity line

Newron reports positive Phase II safety and tolerability results for HF0220 in Alzheimer’s disease

New Safinamide patent granted by European Patent Office (EPO)

Newron awarded EUR 5 million by the Italian government

Newron reports half-year results 2008

Newron to be included in SXI Life Sciences and SXI Bio+Medtech Indices of SWX

Newron announces completion of patient enrollment in phase III clinical trial of safinamide in mid- to late-stage Parkinson’s Disease

Newron closes acquisition of Hunter-Fleming

Newron acquisition of Hunter-Fleming. Upfront payment agreed.

Newron shareholders’ meeting

NEWRON TO BE INCLUDED IN SWISS PERFORMANCE INDEX OF THE SWISS STOCK EXCHANGE (“SWX”) EFFECTIVE 6 MAY 2008

Newron reports positive Phase II results for ralfinamide in peripheral neuropathic pain patients

Newron to present Phase II clinical data on ralfinamide in neuropathic pain at the AAN

NEWRON PHARMACEUTICALS REPORTS 2007 RESULTS

Data safety monitoring board recommends continuation of phase II study for HF0220 in patients with Alzheimer’s disease

Safinamide patent protection strengthened by EPO Intention-to-Grant-letter

Newron completes enrolment of clinical phase II study with ralfinamide in post-surgical (dental) pain

Newron acquires Hunter-Fleming Ltd

Dr. Hans-Joachim Lohrisch joins Newron’s Board of Directors